IQVIA Holdings Inc. logo
IQVIA Holdings Inc. (IQV)
Compare

IQVIA Holdings Inc. (IQV) PE Ratio: 23.08

popular:market cap|pe ratio|revenue|price history|total return

Is IQVIA Holdings Inc.’s P/E ratio high or low?

IQVIA Holdings Inc.'s P/E ratio of 23.08 is 40% below its 5-year average of 38.55, near the low end of its 5-year range (18.66–120.35).

The P/E ratio for IQVIA Holdings Inc. (IQV) is 23.08 as of Tuesday, June 9, 2026. It is below its 12-month average by 11.14% (25.97).

PE Ratio (23.08) = Close Price ($186.25) / Diluted TTM EPS ($8.07)

PEG Ratio|P/B Ratio|EPS|All Metrics

IQV PE Ratio Chart

IQV PE Ratio
23.08+9.90% 1Y
Zoom

IQV Average PE Ratio Chart

IQV Current vs Average PE Ratio Chart

IQV PE Ratio Metrics

PE RATIO

23.08

PE RATIO AVG TTM

25.97

PE RATIO AVG 3Y

29.33

PE RATIO AVG 5Y

38.55

PE RATIO AVG 10Y

73.12

PE RATIO AVG 15Y

62.04

PE RATIO AVG 20Y

62.04

CURRENT VS TTM AVG

-11.14%

CURRENT VS 3Y AVG

-21.30%

CURRENT VS 5Y AVG

-40.14%

CURRENT VS 10Y AVG

-68.44%

CURRENT VS 15Y AVG

-62.80%

CURRENT VS 20Y AVG

-62.80%

IQV Competitors' PE Ratio

NAMEMARKET CAPPE RATIOTTM3Y5Y
IQVIA Holdings Inc. (IQV)—23.0825.9729.3338.55
DexCom, Inc. (DXCM)$30.17B33.4142.1371.74113.70
Centene Corporation (CNC)$32.69BN/A9.3712.4922.33
Biogen Inc. (BIIB)$29.39B21.3216.5018.4918.66
Zoetis Inc. (ZTS)$34.46B13.6322.1930.4935.47
Veeva Systems Inc. (VEEV)$27.37B29.8947.2254.6966.93
Waters Corporation (WAT)$24.19B47.1631.8530.8930.42
Agilent Technologies, Inc. (A)$38.26B27.2029.3529.8132.79
Mettler-Toledo International Inc. (MTD)$23.50B27.2332.0132.8136.46
BioNTech SE (BNTX)$21.87BN/A237.28176.83109.05

P/E vs. its own history

At 23.1, P/E is cheaper than usual — richer than 20% of its 13-year range.

13-year low

15.7

median

31.8

13-year high

374.3

cheaperricher

P/E Comparison

Trailing P/E

23.1

Forward P/E

13.2

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$186.25

÷

Forward EPS (Est.)

$14.15

=

Forward P/E

13.16

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

IQVIA Holdings Inc. PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

IQVIA Holdings Inc. PE Ratio FAQ

What is the P/E ratio for IQVIA Holdings Inc. (IQV)?
The P/E ratio for IQV stock is 23.08.
Is IQVIA Holdings Inc.'s P/E ratio high or low?
IQVIA Holdings Inc.'s P/E ratio of 23.08 is 40% below its 5-year average of 38.55, near the low end of its 5-year range (18.66–120.35).
What is the TTM average P/E ratio for IQVIA Holdings Inc. (IQV)?
The TTM average P/E ratio for IQV stock is 25.97.
What is the 3Y average P/E ratio for IQVIA Holdings Inc. (IQV)?
The 3Y average P/E ratio for IQV stock is 29.33.
What is the 5Y average P/E ratio for IQVIA Holdings Inc. (IQV)?
The 5Y average P/E ratio for IQV stock is 38.55.
What is the 10Y average P/E ratio for IQVIA Holdings Inc. (IQV)?
The 10Y average P/E ratio for IQV stock is 73.12.
What is the 15Y average P/E ratio for IQVIA Holdings Inc. (IQV)?
The 15Y average P/E ratio for IQV stock is 62.04.
What is the 20Y average P/E ratio for IQVIA Holdings Inc. (IQV)?
The 20Y average P/E ratio for IQV stock is 62.04.

IQVIA Holdings Inc. PE Ratio History

DATEPE RATIO
2026-06-0923.08
2026-06-0822.76
2026-06-0522.73
2026-06-0423.16
2026-06-0322.56
2026-06-0222.38
2026-06-0123.15
2026-05-2922.58
2026-05-2822.44
2026-05-2720.52
2026-05-2620.07
2026-05-2220.81
2026-05-2120.82
2026-05-2021.25
2026-05-1921.46
2026-05-1821.41
2026-05-1520.96
2026-05-1421.15
2026-05-1321.36
2026-05-1221.69
2026-05-1121.51
2026-05-0822.14
2026-05-0722.14
2026-05-0621.87
2026-05-0521.86
2026-05-0420.48
2026-05-0120.07
2026-04-3020.15
2026-04-2919.93
2026-04-2820.23
2026-04-2720.84
2026-04-2420.65
2026-04-2320.44
2026-04-2222.29
2026-04-2122.35
2026-04-2022.49
2026-04-1722.45
2026-04-1621.88
2026-04-1522.66
2026-04-1422.30
2026-04-1321.88
2026-04-1021.29
2026-04-0921.50
2026-04-0821.95
2026-04-0721.71
2026-04-0621.72
2026-04-0222.04
2026-04-0121.93
2026-03-3121.70
2026-03-3021.14
2026-03-2720.85
2026-03-2621.55
2026-03-2521.07
2026-03-2421.13
2026-03-2321.24
2026-03-2021.13
2026-03-1921.18
2026-03-1821.25
2026-03-1721.43
2026-03-1620.98
2026-03-1320.96
2026-03-1220.73
2026-03-1121.83
2026-03-1021.75
2026-03-0922.72
2026-03-0622.20
2026-03-0522.71
2026-03-0422.63
2026-03-0322.13
2026-03-0222.17
2026-02-2722.75
2026-02-2621.71
2026-02-2520.60
2026-02-2420.98
2026-02-2320.65
2026-02-2021.07
2026-02-1921.55
2026-02-1821.76
2026-02-1720.92
2026-02-1322.90
2026-02-1223.16
2026-02-1124.30
2026-02-1025.03
2026-02-0926.43
2026-02-0625.72
2026-02-0524.82
2026-02-0427.78
2026-02-0327.95
2026-02-0231.72
2026-01-3031.57
2026-01-2932.32
2026-01-2832.89
2026-01-2733.06
2026-01-2632.84
2026-01-2332.28
2026-01-2232.79
2026-01-2133.11
2026-01-2032.06
2026-01-1632.60
2026-01-1533.10
2026-01-1433.11
2026-01-1333.14
2026-01-1233.04
2026-01-0933.25
2026-01-0833.36
2026-01-0733.51
2026-01-0632.99
2026-01-0532.18
2026-01-0230.91
2025-12-3130.92
2025-12-3031.23
2025-12-2931.15
2025-12-2631.13
2025-12-2431.00
2025-12-2330.88
2025-12-2230.78
2025-12-1930.27
2025-12-1830.52
2025-12-1730.37
2025-12-1630.41
2025-12-1530.68
2025-12-1230.49
2025-12-1131.00
2025-12-1030.58
2025-12-0929.91
2025-12-0830.67
2025-12-0530.98
2025-12-0430.85
2025-12-0331.17
2025-12-0230.95
2025-12-0131.34
2025-11-2831.55
2025-11-2631.80
2025-11-2531.81
2025-11-2431.30
2025-11-2130.85
2025-11-2029.78
2025-11-1929.83
2025-11-1829.81
2025-11-1729.65
2025-11-1430.26
2025-11-1330.67
2025-11-1230.30
2025-11-1129.98
2025-11-1029.22
2025-11-0728.87
2025-11-0628.92
2025-11-0528.82
2025-11-0428.94
2025-11-0329.34
2025-10-3129.69
2025-10-3029.69
2025-10-2929.88
2025-10-2829.92
2025-10-2731.47
2025-10-2431.91
2025-10-2331.82
2025-10-2231.53
2025-10-2131.65
2025-10-2030.69
2025-10-1729.60
2025-10-1629.78
2025-10-1529.40
2025-10-1429.63
2025-10-1329.49
2025-10-1028.68
2025-10-0929.38
2025-10-0829.03
2025-10-0729.07
2025-10-0629.67
2025-10-0329.90
2025-10-0229.57
2025-10-0129.49
2025-09-3027.49
2025-09-2926.15
2025-09-2625.99
2025-09-2525.57
2025-09-2426.23
2025-09-2326.98
2025-09-2227.18
2025-09-1927.09
2025-09-1827.53
2025-09-1727.02
2025-09-1627.03
2025-09-1526.91
2025-09-1227.09
2025-09-1127.60
2025-09-1026.61
2025-09-0927.44
2025-09-0827.16
2025-09-0527.16
2025-09-0426.64
2025-09-0326.72
2025-09-0226.59
2025-08-2927.61
2025-08-2827.31
2025-08-2727.32
2025-08-2627.17
2025-08-2527.21
2025-08-2227.66
2025-08-2126.83
2025-08-2027.79
2025-08-1927.84
2025-08-1827.86
2025-08-1527.65
2025-08-1427.41
2025-08-1327.53
2025-08-1226.90
2025-08-1126.06
2025-08-0826.03
2025-08-0725.90
2025-08-0625.69
2025-08-0526.62
2025-08-0426.45
2025-08-0126.40
2025-07-3126.90
2025-07-3027.72
2025-07-2928.15
2025-07-2828.62
2025-07-2528.82
2025-07-2429.06
2025-07-2328.11
2025-07-2227.12
2025-07-2121.66
2025-07-1821.88
2025-07-1722.24
2025-07-1621.61
2025-07-1521.48
2025-07-1421.82
2025-07-1122.18
2025-07-1022.55
2025-07-0922.07
2025-07-0822.41
2025-07-0722.13
2025-07-0322.38
2025-07-0222.43
2025-07-0122.15
2025-06-3021.47
2025-06-2721.45
2025-06-2621.55
2025-06-2521.62
2025-06-2421.60
2025-06-2321.14
2025-06-2021.08
2025-06-1821.06
2025-06-1720.99
2025-06-1621.70
2025-06-1321.37
2025-06-1221.68
2025-06-1121.64
2025-06-1021.77
2025-06-0921.00
2025-06-0620.75
2025-06-0520.08
2025-06-0420.15
2025-06-0319.45
2025-06-0218.95
2025-05-3019.12
2025-05-2919.21
2025-05-2818.91

Showing the most recent 260 of 3,291 data points. The chart above shows the full history.

Related Metrics

PEG RatioP/B RatioEPSAll Metrics

About IQVIA Holdings Inc.

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

Durham, NC
89,000 employees
www.iqvia.com
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Ari Bousbib
View full financials